

ASX Announcement

Race Oncology Upcoming 2025 Investor Events

15 July 2025 – Race Oncology Limited (“Race”) is pleased to announce it will be participating in a number of upcoming investor events and conferences in Australia and Hong Kong in 2025.

Investor Briefing in Hobart, Tasmania – 6 August 2025

Race Oncology wishes to invite shareholders and potential new investors to attend an in-person investor briefing and light lunch in Hobart on 6 August 2025.

Executive Chairman, Dr Pete Smith and Managing Director and Chief Executive Officer, Dr Daniel Tillett will both present an update, then host a Q+A session.

Briefing details

Date: Wednesday 6 August 2025
Time: 12:15pm for a 12:30pm start
Location: Wapping Room
The Old Woolstore Apartment Hotel
1 Macquarie Street
Hobart, Tasmania
Format: Light lunch and an investor briefing with live Q+A
RSVP: By Monday 28 July to anna.cvijetic@irdepartment.com.au
Please advise any dietary requirements.

19th Bioshares Biotech Summit in Hobart, Tasmania – 7-8 August 2025

The Race team will also be meeting with investors and industry peers at the 19th Bioshares Biotech Summit.

Conference details

7-8 August 2025 at Hotel Grand Chancellor, Hobart, Tasmania.

For registration and program details, please visit the Bioshares website [here](#).

TechKnow Invest Roadshow in Melbourne and Sydney - 19 & 21 August 2025

Race invites investors in Melbourne and Sydney to join us at the *TechKnow Invest Roadshow* on 19 August 2025 in Melbourne and 21 August 2025 in Sydney. The *TechKnow Investor Roadshow* will feature ASX-listed tech and medtech companies, showcasing investment opportunities within the sector.

Race's Executive Chair, Dr Pete Smith will be presenting at the Melbourne event and CEO, Dr Daniel Tillett will be presenting at the Sydney event. Investors are invited to register for free to attend the event, as well as to meet and speak with Dr Smith and Dr Tillett at Race's kiosk.

Conference details

Melbourne - 19 August 2025 at Rydges, Melbourne, Victoria.

Sydney – 21 August 2025 at Swissôtel, Sydney, New South Wales.

For registration and program details, please visit the *Techknow Invest Roadshow* website [here](#).

Investor Briefing, Hong Kong – 14-16 October 2025

Race will be conducting investor meetings in Hong Kong from 14 – 16 October.

Save the date: Investor Briefing in Hong Kong – 14 October 2025

On 14 October 2025, Race will host a lunch briefing at a central Hong Kong location, with venue details to be confirmed. The lunch is expected to commence at 12:15pm for a 12:30pm start.

To register your interest in attending the lunch, please email anna.cvijetic@irdepartment.com.au.

Race will release details of the venue closer to the event.

Hong Kong Ignite Investment Summit

Race invites investors in Hong Kong to join us at the Ignite Investment Summit on 15-16 October 2025.

Hosted by Ignite Partners, the Ignite Investment Summit features world-class keynote speakers, investor-led panels and CEO presentations.

Race Executive Chair, Dr Pete Smith and CEO, Dr Daniel Tillett will be presenting at the two-day event.

Conference details

Date: 15-16 October

Location: Grand Hyatt Hong Kong.

Shareholders and investor attendees are invited to register for free to attend the event via this [link](#).

The Race team looks forward to seeing all those who can join us at these events.

-ENDS-



About Race Oncology (ASX: RAC)

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care.

Race's lead asset, bisantrene, is a small molecule anticancer agent. Bisantrene has a rich and unique clinical history with demonstrated therapeutic benefits in both adult and paediatric patients, a well characterised safety profile, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin.

Race is advancing a reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where we hope to deliver cardioprotection and enhanced anti-cancer activity in solid tumours. Race is also exploring RC220 as a low intensity treatment for acute myeloid leukaemia.

Race Oncology has collaborated with Astex, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong and University of Newcastle, and is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to bisantrene for patients with cancer across the world.

Learn more at www.raceoncology.com.

If you have any questions on this announcement or any past Race Oncology announcements, please go to the Interactive Announcements page in our Investor Hub <https://announcements.raceoncology.com>

Race encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by:

Daniel Tillett, CEO
info@raceoncology.com

Media contact:

Jane Lowe +61 411 117 774
jane.lowe@irdepartment.com.au

For personal use only